Adaptable clinical trials are an exciting opportunity, but federal agencies working in this areas need to coordinate and collaborate. What about a trial that is not successful by an initial protocol definition, but DOES show a treatment works for a key subset of patients, should that trial, that valuable information, that research, those efforts and resources be considered a waste? Should the researchers have to start from scratch, wasting time, and money that patients in need can not afford to lose.
Regarding encouraging clinical trial participation, there is so much we can do! Working with patient communities to identify and break down barriers is crucial, but so is working with providers to encourage them to engage their patients in research opportunities. Researchers must also be encouraged and continuously strive for quality and efficiency in their work.
Subscribe to:
Post Comments (Atom)
This information is crucial and all information needs to dissemated on the individual and group level.
ReplyDeleteAn immunologist once did a blood test to check my mannose-binding lectin level because he heard about it at a seminar. My results were not normal and nothing has ever been done. I have researched the info and many things i have going on could be attributed (and corrected) to this deficiency of my innate immune system.
How to be able to link information between doctors,laypersons and researchers.